The JAK2/STAT3 signaling pathway can up-regulate the expression of PD-L1 in CD169+ macrophages, but cannot up-regulate the expression of PD-L1 in breast cancer cells, thus avoiding immune surveillance [66]. Here, STAT3 is linked to breast cancer.